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Abstract
Background: High grade primary bone sarcomas are rare cancers that affect mostly children and young adults.
Osteosarcoma and Ewing sarcoma are the most common histological subtypes in this age group, with current
multimodality treatment strategies achieving 55-70% overall survival. As there remains an urgent need to develop
new therapeutic interventions, we have reviewed published phase I/II trials that have been reported for
osteosarcoma and Ewing sarcoma in the last twenty years.
Results: We conducted a literature search for clinical trials between 1990 and 2010, either for trials enrolling bone
sarcoma patients as part of a general sarcoma indication or trials specifically in osteosarcoma and Ewing sarcoma.
We identified 42 clinical trials that fulfilled our search criteria for general sarcoma that enrolled these patient
groups, and eight and twenty specific trials for Ewing and osteosarcoma patients, respectively. For the phase I trials
which enrolled different tumour types our results were incomplete, because the sarcoma patients were not
mentioned in the PubMed abstract. A total of 3,736 sarcoma patients were included in these trials over this period,
1,114 for osteosarcoma and 1,263 for Ewing sarcoma. As a proportion of the worldwide disease burden over this
period, these numbers reflect a very small percentage of the potential patient recruitment, approximately 0.6% for
Ewing sarcoma and 0.2% for osteosarcoma. However, these data show an increase in recent activity overall and
suggest there is still much room for improvement in the current trial development structures.
Conclusion: Lack of resources and commercial investment will inevitably limit opportunity to develop sufficiently
rapid improvements in clinical outcomes. International collaboration exists in many well founded co-operative
groups for phase III trials, but progress may be more effective if there were also more investment of molecular and
translational research into disease focused phase I/II clinical trials. Examples of new models for early translational
and early phase trial collaboration include the European based EuroBoNeT network, the Sarcoma Alliance for
Research through Collaboration network (SARC) and the new European collaborative translational trial network,
EuroSarc.
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Primary bone sarcomas are rare, and account for
approximately 6% of all childhood malignancies, with
Ewing sarcoma and osteosarcoma accounting for
approximately 3% of tumours arising in teenagers. Here
we focus on osteosarcoma and Ewing sarcoma, the two
most common bone sarcomas, whose treatments are
similar as they involve multimodality treatment with
dose intensive and toxic chemotherapy, combined with
potentially mutilating surgery.
Osteosarcoma is the most common primary malignant
tumour arising from bone. It is a pleiomorphic tumour
of bone, and based on animal model systems, thought to
arise in mesenchymal stem cells in which the mutant
proliferating spindle cells produce osteoid or immature
bones [1]. The EMEA published data in 2009 estimating
approximately five people in 1,000,000 in the European
Union (EU) are affected by osteosarcoma. Recently, data
from the RARECARE surveillance network revealed an
incidence of 0.23 per 100,000, amounting to approxi-
mately 1135 new cases per year in EU27 [2]. Osteosar-
coma mostly affects children and young adults with the
median age of diagnosis being fifteen. Seventy-five per-
cent of patients are between eight and twenty-five years
old. Osteosarcoma is often located in the extremities of
long bones near metaphyseal growth plates. Current
treatments for osteosarcoma achieve 60-70% event-free
survival (EFS) for patients who present with localized
disease and approximately 20% EFS for patients with
clinically detectable metastatic disease [3]. Of all
patients, 20% have clinically detectable metastatic dis-
ease at first presentation. Surgical resection of all clini-
cally detectable sites of disease and systemic therapy to
control microscopic metastatic disease is currently the
therapy of choice for early stage osteosarcoma. Since the
introduction of neo-adjuvant and adjuvant chemother-
apy to surgery in the early 1980s, the long term survival
of patients with osteosarcoma has remained stable at
about 60-65%. In terms of chemotherapy, several agents
have demonstrated activity in osteosarcoma including
cisplatin, doxorubicin, high-dose methotrexate with leu-
covorin rescue (HDMTX) and ifosfamide. For current
treatment options these agents are combined. Since the
early 1980s, trials have been conducted in which the
variations in doses and scheduling between these four
agents were tested, but these have not result in improve-
ment of EFS [4]. Since the introduction of ifosfamide,
more than two decades ago, the only new agent that has
been approved is muramyl tripeptide, a drug that acti-
vates the innate immune system [5]. Thus, despite surgi-
cal resection of the primary tumour and aggressive
adjuvant chemotherapy, 30%-40% still die of metastases
that are resistant to conventional therapies [6-8]. For
osteosarcoma patients with resectable pulmonary metas-
tases it has become more standard to treat these
patients with metastectomy. This has been shown to
improve relapse free survival and a subgroup of patients
may even be cured [9].
Ewing Sarcoma/Primitive Neuroectodermal (PNET)
are the second most common bone malignancy after
osteosarcoma in children and young adults with a peak
incidence at age fifteen. Ewing sarcoma are diagnosti-
cally defined by a Ewing sarcoma EWS (Chromosome
22) translocation resulting in fusion with an ETS tran-
scription factor, the commonest abnormality (85%)
being EWS-FLI1 (Chromosome 11) or rarely with a non
ETS family partner [10,11]. Although claimed in the
past that the transcript type reflected a difference in
prognoses [12] this proved not to be the case in pro-
spective randomised trials [13]. RARECARE estimates
an EU27 incidence rate for bone and soft tissue Ewing
sarcoma of 0.13 per 100,000 and 0.05 per 100,000,
respectively [2]. This translates to approximately 647
bone and 263 soft tissue new Ewing sarcoma diagnoses
per year (EU27), with a predicted 65-75% 5 year survival
for non-metastatic disease using conventional che-
motherapy, radiotherapy, high dose chemotherapy and
peripheral blood stem cell transplant (PBSCT). However,
survival for the 25% of patients that present with meta-
static disease is approximately 20% [14], and for those
who develop relapsed and/or refractory disease, the sur-
vival is no more that 10%. To date, studies in the patient
population requiring salvage treatment have been con-
fined to chemotherapy combinations and high dose che-
motherapy, with variable response rates and little or no
impact on survival. During the last two decades, the
outcome has improved in patients with localized disease.
This has been achieved by dose intensification and stan-
dardisation of conventional therapeutics and radiother-
apy. With the use of multidisciplinary treatments, such
as chemotherapy (including vincristine, doxorubicin,
cyclophosphamide, ifosfamide and etoposide), surgery
and radiation therapy, the five year overall survival prob-
ability exceeds 75% for patients with non metastatic low
volume Ewing sarcoma. However, advances in the treat-
ment of Ewing sarcoma have not impacted on the out-
come of patients with large volume and metastatic
disease [15].
In the last two decades the treatment outcome for
these bone sarcomas has not improved greatly, even
though some new treatment interventions have been
successfully tested. Large scale phase III trials with long
durations of recruitment have established material for
prognostic and treatment related correlative studies with
survival and toxicity outcomes, and importantly, have
formed the basis of international collaboration.
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tant in order to develop proof of principle single agent
and combination treatments, particularly with newer
molecular and biological based interventions that
directly test disease specific molecular mechanisms.
We wished to establish the effective level of phase I/II
activity that has been reported in peer reviewed publica-
tions in the last twenty years. We report an overview of
the phase I/II trials that have been conducted for osteo-
sarcoma and Ewing sarcoma, where we detail the kind
of drugs that have been tested, what the published study
outcomes were and what interventions have progressed
to testing in phase III trials. The results show an
improvement in overall activity, but that the number of
studies and International collaborations in early phase
trials remain at a low and limited level. We discuss
potential routes to improve the number and quality of
early phase trials in Ewing and osteosarcoma.
Methods
Search strategy
We report data available in the public domain only.
Publications were identified from searches of PubMed,
the Cochrane Controlled Trials Register, American
Society of Clinical Oncology (ASCO) abstracts and Clin-
icalTrials.gov. databases for the period 1990-2010. The
search strategies used terms for osteosarcoma; (osteosar-
coma) AND (phase I OR phase II) AND (clinical trial),
and was supplemented with a text word search. For
Ewing sarcoma the search algorithm was; (Ewing sar-
coma) AND (phase I OR phase II) AND (clinical trial).
To validate the search we broadened the search algo-
rithm to; (sarcoma) AND (phase I OR phase II) AND
(clinical trial), and compared the results from the nar-
row search with the ones from the broad search. The
latest search was performed in April 2010.
Whenever multiple reports from the same trial were
published, we used only the report with the longest fol-
low-up to avoid any duplication of information. Publica-
tions were eligible if they: (1) described (or cited a paper
that described) osteosarcoma or Ewing sarcoma study of
early phase clinical trials; (2) were published in English;
and (3) came from industrialized countries. All types of
evaluation were accepted (full papers, conference
abstracts, reports) as long as results (including data)
were presented.
Data extraction
Data extraction was conducted independently by two
authors (A. B. and A.M. van M.). We used a systematic
method for the search normally used for meta-analysis
[16]. Differences in data extraction were resolved by
consensus with a third author (A.B. H.). From each eli-
gible trial we recorded authors’ names, journal and year
of publication, number of patients enrolled, number of
osteosarcoma or Ewing sarcoma patients, study phase
and the outcome of the trial.
Results and discussion
Eligible trials
A flow-chart indicating the identification of clinical trials
for inclusion in the analysis is reported for Ewing sar-
coma (Figure 1A) and osteosarcoma (Figure 1B). During
the search many reports had to be excluded because no
results were published. When we searched the reports
using full text, we had to exclude some papers because
neither osteosarcoma nor Ewing sarcoma patients were
included in these studies. When we combined the
results, we identified 42 trials enrolling patients with
any histological diagnosis of sarcoma that were eligible
for our study, in that they included osteosarcoma and
Ewing sarcoma. Of the 42 clinical trials twenty-one were
phase I, two were phase I/II and nineteen were phase II
trials. We found eight clinical trials which included only
Ewing sarcoma patients; of this group two were phase I
and six were phase II trials. We identified twenty trials
that included only osteosarcoma patients. There were
two phase I, sixteen were phase II and two were phase
I/II trials. A total of 3,736 patients were included in all
the clinical trials, of which 1,263 were Ewing sarcoma
and 1,114 were osteosarcoma patients.
Primary Outcome
Tables 1 and 2 show the search results for clinical trials
conducted in patients with the wider diagnosis of gen-
eral sarcoma, and specifically the trials that included
either osteosarcoma (Table 3) or Ewing sarcoma
patients only (Table 4). Table 1 and 2 are trials testing
either chemotherapy or biological treatments, respec-
tively. Analysis of the number of trials conducted which
included only osteosarcoma or Ewing sarcoma patients
from 1990 to the present, (Figure 2A) it was clear that
the number of trials reported for osteosarcoma has been
stable since 1995, with approximately five trials in five
years. For Ewing sarcoma there has been an increase in
the number of trials published, with the no early phase
trials reported between 1990 and 1999, an increasing
number of trials in the period 2000-2005 and even more
between 2006-2010.
For the number of patients enrolled in the eligible trials
the results were disappointing (Figure 2B), with an
almost stable number of patients in osteosarcoma trials,
except for 1999, 2005 and 2009 when the results from
larger phase II trials were published (Table 3). For Ewing
sarcoma there were increasing numbers of patients in
early phase trials, especially in 2008 when the result of
the largest trial in Ewing sarcoma patients was published
(Table 4). Out of all the 780 osteosarcoma patients
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patients, 762 were evaluable and 58 patients (8%)
achieved complete response (CR), 21 (2.8%) showed par-
tial response (PR) and 30 (4%) developed stable disease
(SD). For the trials enrolling only Ewing sarcoma
patients, 869 were recruited and 840 were evaluable, 80
had CR (9.5%), 63 (7.5%) showed PR and 23 (3%) devel-
oped SD.
Looking at the trials subdivided for chemotherapy or
biological treatment (Tables 1 and 2) in the past twenty
years, there seems to have been a shift towards biologi-
cally based treatments instead of chemotherapy. Even so
most of the phase III trials are still chemotherapy based
treatments.
For current ongoing phase I and phase II studies we
found 156 trials that are open and recruiting sarcoma
patients. These trials recruit sarcoma patients in general
or patients with solid tumours or soft tissue sarcoma.
Studies enrolling only osteosarcoma or Ewing sarcoma
patients are rare. For osteosarcoma we found four trials
that are recruiting patients and two that are already
active but not yet recruiting patients (Table 5). Of the
trials two were testing chemotherapy treatment, three
biologically agents and one a combination of both. For
Ewing sarcoma we found no trials that enrol only Ewing
patients and two that are still active but not currently
enrolling patients.
When searching for studies that are enrolling sarcoma
patients we found a number of trials that were prelimin-
ary stopped. For example SARC011, this is a phase II
trial of R1507, a recombinant human monoclonal anti-
body to the Insulin-like growth factor-1 receptor for the
treatment of patients with recurrent or refractory Ewing
sarcoma, osteosarcoma, synovial sarcoma, rhabdomyo-
sarcoma and other sarcomas. In December 2009, Roche/
Genentech decided to discontinue the development of
their IGF-1R antibody although the drug had shown
important clinical benefit http://www.cancer.gov/ncican-
cerbulletin/111610/page5. Roche said the decision was
due to the available clinical data, the large number of
molecules targeting the same pathway that are presently
in development and the prioritization of the Roche
Figure 1 Flowchart diagrams of the clinical trial selection criteria outcomes for Ewing sarcoma (A) and osteosarcoma (B).
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Author Year Intervention No Osteo
patients
No Ewing
Patients
Phase Outcome
Pratt et al, Cancer, 74: 2593-8 [22] 1994 Leucovorin, 5-Fluorouracil 22 12 II Ewing: 3 (25%) SD, Osteo: 1 (5%)
SD
Kushner et al, J Clin Oncol, 13 (11): 2796-804 [23] 1995 Cyclo, Doxo, Etop, Ifos, Vin Not mentioned Not mentioned II 6 (17%) CR, 2 (6%) PR, 34 (95%)
CIR
Antman et al, Cancer, 82 (7): 1288-95 [24] 1998 Doxo, Dacarbazine, Ifos 31 13 II 10 (12%) CR, 34 (42%) PR
Blaney et al, Clin Cancer Res, 4 (2): 357-60 [25] 1998 Topotecan 18 25 II 1 (1%) CR, 1 (1%) PR, 8 (9%) SD
Lucidarme et al, Bone Marrow Transplant, 22 (6): 535-40
[26]
1998 Thiotepa combined with SCR 7 3 II 11 (50%) PR
Berg et al, J Pediatric Hematol Oncol, 22 (6): 506-9 [27] 2000 Pyrazoloacridine 8 10 II 0% response
Delaloge et al, J Clin Oncol, 19 (5): 1248-55 [28] 2001 Trabectedin 3 1 I 4 (14%) CR, 10 (35%) SD
Saylors et al, J Clin Oncol, 19 (15): 3463-9 [29] 2001 Cyclo and Topotecan 18 17 II 6 (35%) OR
Wagner et al, Clin Cancer Res, 10 (3): 840-8 [30] 2004 Temozolomide, Irinotecan 0 7 I 1 (8%) CR, 2 (17%) PR
Lau et al, Clin Cancer Res, 11: 672-7 [31] 2005 Trabectedin 4 3 I 1 (8%) CR
van Winkle et al, Pediatr Blood Cancer, 44 (4): 338-47
[32]
2005 Ifos, Carboplatin and Etop 35 22 I/II Not mentioned
Hawkins et al, Pediatr Blood Cancer, 47 (6): 328-37 [33] 2006 Topotecan 11 20 II 2 (4%) PR
Navid et al, Cancer, 106 (8): 1846-56 [34] 2006 Vin, Doxo, Cyclo, Ifos and Etop 0 11 II 47 (66%) CR
Wagner-Bohn et al, Cancer, 46 (2): 262 [35] 2006 Gemcitabine 2 4 II 2 (10%) SD
Zaucha et al, Int J Rad Oncol Biol Phys, 64 (1): 227-34
[36]
2006 Total body radiation after high-dose
chemotherapy
0 10 II 13 (25%) CR, 10 (19%) PR
Zwerdling et al, Cancer, 106 (8): 1821-8 [37] 2006 Docetaxel 23 21 II 2 (1%) CR, 6 (3%) PR, 17 (10%) SD
Geoerger et al, J Clin Oncol, 26: 4394-400 [38] 2008 Oxaliplatin 6 2 I 2 (4%) PR, 17 (6%) SD
Geler et al, Pediatr Blood Cancer, 52 2009 Paclitaxel, Ifos 1 3 I 3 (20%) PD, 5 (33%) SD
Wagner et al, ASCO abstract 2009 Vin, Irinotecan, Temozolomide 3 5 I 1 (3%) PR,2 (6%) OR
McGregor et al, Cancer, 115 (8): 1765-75 [39] 2009 Oxaliplatin, Irinotecan 6 1 I 1 (8%) CR, 1 (8%) SD
Abbreviations: ClR = Clinical Response; CR = Complete Response; Cyclo = cyclophosphamide; Doxo = doxorubicine; EFS = Event Free Survival; Etop = etoposide; Ewing = Ewing Sarcoma; Ifos = ifosfamide; No =
number; OR = Objective Response; Osteo = Osteosarcoma; PD = Progressive Disease; PR = Partial Response; RR = Response Rate; SCR = Stem Cell Rescue; SD = Stabile Disease; TMR = Total Marrow Radiation; Vin =
vincristine
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5Table 2 Characteristics of eligible trials for general sarcoma with biologically based treatment for phase I and phase II
Author Year Intervention No Osteo Patients No Ewing Patients Phase Outcome
Daw et al, J Clin Oncol, 23 (25): 6172-80 [40] 2005 Gefitinib 6 3 I 1 (4%) PR, 4 (16%) SD
Maki et al, Cancer, 103 (7): 1431-8 [41] 2005 Bortezomib 1 2 II 1 (4%) OR
Villablanca et al, J Clin Oncol, 24 (21): 3423-30 [42] 2006 Fenretinide 2 5 I 1 (2%) CR, 13 (24%) SD
Biron et al, ASCO abstract 2007 Gimatecan 0 Not mentioned II 3 (8%) SD
Bagatell et al, Clin Cancer Res, 13 (6): 1783-8 [43] 2007 Tanespimycin 6 2 I 0% OR
Jimeno et al, Pediatr Blood Cancer, 49 (3): 352-7 [44] 2007 Gefitinib 3 1 I 1 (7%) PR, 3 (20%) SD
Kramer et al, J Clin Oncol, 25 (34): 5465-70 [45] 2007 Monoclonal antibody(131-I-3F8) 0 2 I 3 (23%) ClR
Bond et al, Pediatr Blood Cancer, 50 (2): 254-8 [46] 2008 Imatinib mesylate 10 24 II 1 (1%) PR
Chao et al, ASCO abstract 2008 Imatinib mesylate 0 7 II 1 (14%) PR
Fox et al, Clin Cancer Res, 14 (4): 1111-5 [47] 2008 Tubulin Inhibitor (ABT-751) 3 3 I 0% OR
Jakacki et al, J Clin Oncol, 26 (30): 4921-7 [48] 2008 Erlotinib, Temozolomide 1 0 I 1 (2%) SD
Langevin et al, Pediatr Blood Cancer, 50 (3): 577-80 [49] 2008 Rebeccamycin 16 14 II % OR
Mita et al, J Clin Oncol, 26 (3): 361-7 [50] 2008 Deforolimus 1 1 I 4 (13%) PR, 18 (56%) SD
Olmos et al, ASCO abstract 2008 Figitumumab 0 9 I 1 (5%) PR, 6 (27%) SD
Chawla et al, Mol Ther, 17 (9): 1651-7 [51] 2009 Rexin-G 3 1 I/II 13 (65%) SD
Chugh et al, J Clin Oncol, 27 (19): 3148-53 [52] 2009 Imatinib 27 13 II 1 (0.5%) CR, 3 (2%) PR
Malempati et al, ASCO abstract 2009 Cixutumumab Not mentioned 10 I 1 (4%) PR
Patel et al, ASCO abstract 2009 IGF-1R antibody (R1507) 43 71 II Not mentioned
Widemann et al, J Clin Oncol, 27 (4): 550-6 [53] 2009 Ixabepilone 3 2 I 4 (21%) SD
Jacobs et al, Clin Cancer Res, 16 (2): 750-4 [54] 2010 Ixabepilone 11 9 II 0% OR
Kurzrock et al, Clin Cancer Res, 16 (8): 2458-65 [55] 2010 IGF-1R antibody (R1507) 0 9 I 2 (5%) PR, 13 (35%) SD
Olmos et al, Lancet Oncol, 11: 129-35 [56] 2010 Figitumumab 0 16 I 1 (3%) CR, 1 (3%) PR, 8 (28%) SD
Abbreviations:, ClR = Clinical Response; CR = Complete Response; Cyclo = cyclophosphamide; Doxo = doxorubicin; EFS = Event Free Survival; Etop = etoposide; Ewing = Ewing Sarcoma; Ifos = ifosfamide; No =
number; OR = Objective Response; Osteo = Osteosarcoma; PR = Partial Response; RR = Response Rate; SCR = Stem Cell Rescue; SD = Stabile Disease; TMR = Total Marrow Radiation; Vin = vincristine
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5Table 3 Characteristics of eligible trials for osteosarcoma only
Author Year Intervention Phase No of
Patients
Outcome
Salesh RA., et al., Cancer 65:861-5. 1990 Etoposide 72-h i.v 600 mg/m
2. Cyclophosphamide 300 mg/m2 every 12 hours for a
total dose of 1800 mg/m2.
II 17 15 (88%) CR or PR
Kleinerman ES, et al J. Clin. Oncol.
10, 1310-6. [57]
1992 L-MTP-PE 2 mg/m
2 infused during a 1-h period twice a wk for 12 wks, then once a
wk for 12 wks.
II 16 Not mentioned
Kleinerman ES, et al Am J Clin
Oncol. 18(2):93-9. [58]
1995 L-MTP-PE, 2 mg/m
2, i.v over a 1-h twice a wk for 12 wks in 12 pts (Group 1). 16 pts
(Group 2) had 2 mg/m
2 L-MTP-PE twice a wk for 12 wks, then once a wk for 12 wks,
for a total of 24 wks.
II 36 2 (6%) SD
Kleinerman ES, et al J.
Immunother. Emphasis Tumor
Immunol., 17, 181-93. [59]
1995 IFO 1.8 g/m
2 for 5 days every 21 days for up to 8 cycles. L-MTP-PE twice weekly for
12 weeks, then once weekly for 12 weeks
IIb 9 Not mentioned
Harris MB, et al Med Ped Oncol
24, 87-92. [60]
1995 Two courses of ifosfamide (2400 mg/m
2 × 5 days) administered 3 wks apart II 33 Stratum 1: 1 (11%) CR, 8 (24%) PR
Stratum 2: 1 (3%) CR, 2 (7%) PR
Patel SR, et al Cancer; 78:741-4.
[61]
1996 Paclitaxel 175 mg/m
2 24-h i.v II 15 0% OR
Gentet JC, et al Eur J Cancer, Vol.
33, No. 2, 232-7 [62]
1997 Two courses of IFO 3 g/m
2/day and etoposide 75 mg/m
2/day for 4 days. II 27 6 (23%) CR, 7 (25%) PR, 5 (23%) SD
Worth LL, et al Clin Cancer Res. 3
(10):1721-9. [63]
1997 IL-1alpha followed by ICE daily for 5 days/3 wks. II 9 3 (34%) PR, 1 (11%) SD
Voûte PA, et al Annals of
Oncology 10: 1211-8. [64]
1999 IFO 3 g/m
2/dl-2, DOX 25 mg/m
2/dl-3 i.v. bolus and CDDP 100 mg/m
2/dl. II 103 5 year survival was 62% in limb-non-metastatic,
41% in axial skeletal and 16% in limb
metastatic patients.
Fagioli F, et al Journal of Clinical
Oncology, Vol 20, Issue 8:2150-6
[65]
2002 High-dose chemotherapy consisted of carboplatin and etoposide followed by stem-
cell rescue.
I 32 25 (78%) CR, 6 (19%) PD,
3 year OS 20%
3 year DFS 12%
Laverdiere C, et al Cancer; 98:832-
40. [66]
2003 Trabectedin 1500 micro g/m
2 as a 24-h i.v every 3 wks. II 25 0% OR
McTiernan A, et al. Sarcoma, Vol.
8, No. 2/3, 71-6. [67]
2004 Docetaxel 100 mg/m
2 1-h i.v every 3 wks II 14 1 (7%) PR, 2 (14%) SD
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5Table 3 Characteristics of eligible trials for osteosarcoma only (Continued)
Ferrari S et al J Clin Oncol
23:8845-52. [68]
2005 Two blocks of high-dose IFO (15 g/m
2), MTX (12 g/m
2), CDDP (120 m g/m
2), and
DOX (75 m g/m
2)
II 182 5-year EFS 64% and OS 77%
Arpaci F, et al Cancer; 104:1058-65.
[69]
2005 2 cycles of CDDP, DOX, and IFO followed by HDC and APBSCT. II 22 3 year: OS was 83% & 70% DFS
McTiernan A, et al Pediatr Blood
Cancer. 46(3):345-50. [70]
2006 IFO 2.5 g/m
2 etoposide 150 mg/m
2 and DOX 20 mg/m
2 on days 1-3, every 21 days,
with interval MTX 12 g/m
2 given on day 14, for a maximum of 8 cycles.
I/II 13 0% OR
Seibel NL, et al Cancer 2007;
109:1646-53. [71]
2007 Topotecan daily x5 followed by chemotherapy (IFO, carboplatin, ICE, alternating with
CDDP and CD.
I 28 1 (6.6%) PR, 1 (6.6%) CLR
2- and 5-year EFS rates 7% & 4%, resp, 2- and
5-year OS rates 44% and 22%, resp.
Basaran M, et al Oncology;72:255-
60 [72]
2007 Epirubicin 90 mg/m
2 cisplatin 100 mg/m
2 on day 1 and IFO 2.0 g/m
2 day with an
equivalent dose of mesna on days 2-4, repeated every 21 days
II 38 10 (26%) CR, 5 year DFS 41.9%, OS 48.2%.
Iwamoto Y, et al J Orthop Sci
14:397-04. [73]
2009 Preoperative chemotherapy: HD-MTX, CDDP, and ADR. II 113 5 year OS 77.9%
5 year EFS 65.5%
Berger M, et al Cancer 115: 2980
-7. [74]
2009 Cyclophosphamide 4 g/m
2 on Day 1 followed by etoposide at 200 mg/m
2 on Days
2, 3, and 4.
II 26 9 (35%) SD, OS at 1 yr 50%, PFS 42%
Chawla S P, et al Mol Ther.
17:1651-7. [51]
2009 Escalating doses of Rexin-G i.v from 8 × 10
11 to 24 × 10
11 colony forming units (cfu)/
cycle.
II
I/II
Osteo =
22
Sar = 20
Osteo =
0
10 (58.8%) SD
3 (50%) SD(lowest dose)
10 (71%) SD(higher dose)
Abbreviations- ADR = adriamycin; APBSCT = autologous peripheral blood stem cell support transplantation; CDDP = cisplatin; Cfu = colony forming units; CR = complete response; DOX = doxorubicin; EFS = event
free survival; GCSF = Granulocyte colony-stimulating factor; HD-MTX = High-dose Methotrexate; ICE = etoposide; IFO = ifosfamide; IL-6 = interleukin -6; IL-8 = interleukin-8; L-MTP-PE = liposomal muramyl tripeptide
phosphatidyl ethanolamine; MTX = methotrexate; OR = objective response; PD = progressive disease; PFS = progression free survival; OS = overall survival; RDI = relative dose intensity; resp = respectively; Sar =
sarcoma; TNF = tumour necrosis factor
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5Table 4 Characteristics of eligible trials for Ewing sarcoma only
Author Year Intervention Phase No of
Patients
Outcome
Hawkins et al, Med Pediatric
Oncol, 34 (5): 328-37 [33]
2000 Myeloablative therapy followed by HSCT. I 16 3-year EFS 36%
Kolb et al, J Clin Oncol, 21 (18):
3423-30 [75]
2003 7 cycles of chemotherapy consisted of Cyclo, Doxo, Vin, Ifos and Etop II 68 29 (43%) CR, 13 (19%) PD or SD
Meyer et al, Sarcoma, 7 (1): 13-7
[76]
2003 Doc thrice weekly for a maximum of six cycles. II 14 1 (14%) PR, 2 (28%) SD
Bernstein et al, J Clin Oncol, 24
(1): 152-9 [77]
2006 High-dose induction therapy followed by window period. Randomization between topo, topo
+ cyclo or no treatment. No window treatment patients received Amifostine
II 117 45 (43%) CR, 41 (39%) PR, 14 (14%) SD
Womer et al, ASCO abstract 2008 Vin, Doxo and Cyclo alternating with Ifos and Etop, for 14 cycles. Regimen A: 3 weeks cycle,
regimen B: 2 week cycle. Primary tumor treatment was scheduled to begin week 13.
II 587 EFS at a median of 3 years was 65% in
Regimen A and 76% in Regimen B.
Rosenthal et al, Bone Marrow
Transplantation, 42: 311-8 [78]
2008 HDT followed by HSCT. I 22 3-year EFS 47%, 3-year OS 45%
DuBois et al, Pediatric Blood
Cancer, 52 (3): 324-7 [79]
2009 Cytarabine. II 10 1 (10%) SD
Casey et al, Pediatric Blood
Cancer, 53 (6): 1029-34 [80]
2009 Irinotecan and Temozolomide. II 20 5 (25%) CR, 7 (36%) PR
Olmos et al, Lancet Oncol, 11:
129-35 [56]
2010 A subgroup of Ewing Sarcoma patients were treated with Figitumumab I 15 1 (6%) CR, 1 (6%) PR, 6 (37%) SD
Abbreviations: CR = complete response; Cyclo = cyclophosphamide; Doc = docetaxel; Doxo = doxorubucine; EFS = event free survival; Etop = etoposide; G-CSF = granulocyte-colony stimulating factor; HDT = high-
dose chemotherapy; HSCT = hematopoietic stem cell transplantation; Ifos = ifosfamide; OR = overall response; OS = overall survival; PD = progressive disease; PR = partial response; SD = stabile disease; Topo =
topotecan; Vin = vincristine
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5portfolio. The decision was not as a result of safety con-
cerns. Both this study, and a Phase I/II with figitumu-
mab (Pfizer) have been published since completing this
survey, and show low but durable response rates in a
subset of relapsed Ewing patients (10-20%) [17,18].
Bone sarcoma is fatal in approximately one third of
the children and young adults in whom it is diagnosed.
This mortality rate has not changed greatly in the two
decades since the initial introduction of surgery and
chemotherapy. The primary cause of death in treated
Figure 2 Distribution of the number of trials published that have recruited either osteosarcoma or Ewing sarcoma patients between
1990-2010 (A). The total number of either osteosarcoma or Ewing Sarcoma patients entered in phase I/II trials published between 1990-2010 (B).
Table 5 Ongoing phase I or II trials in osteosarcoma (Assessed from www.ClinicalTrials.gov)
ClinicalTrials.
gov Identifier
Sponsors Title Status
NCT00102531 Transave Phase Ib/IIa non-randomised study of SLIT Cisplatin by inhalation in the treatment
of patients with relapsed/progressive osteosarcoma metastatic to the lung
Recruiting
NCT01002092 Shandong Simcere-Medgenn
Bio-pharmaceutical Co., Ltd
A randomized, controlled multicenter trial of Endostar combined with
chemotherapy for treatment of osteosarcoma (phase II)
Recruiting
NCT00889057 Italian Sarcoma Group Phase II, open label, non-randomized study of second or third line treatment with
Sorafenib (BAY 43-9006) in patients affected by relapsed high-grade osteosarcoma
Recruiting
NCT00752206
NCT00923286
Sarcoma Alliance for Research
through Collaboration (SARC)
A randomized, double-blinded, placebo-controlled, multi-institutional, phase II study
of AZD0530, a selective Src kinase inhibitor, in patients with recurrent
osteosarcoma localized to the lung
Recruiting
NCT01005043 University of Heidelberg Phase I/II therapy non-randomised trial to determine the safety and efficacy of
heavy ion radiotherapy in patients with osteosarcoma
Not yet
recruiting
NCT00902044 Baylor College of Medicine Administration of Her2 Chimeric antigen receptor expressing T Cells for subjects
with advanced osteosarcoma (HEROS) (phase I)
Not yet
recruiting
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Page 10 of 15patients is recurrent metastatic disease often to the
lung. In the group of patients who present either with
metastatic or relapsed disease, it is especially important
to conduct biologically based trials with small groups
of patients from which quantitative and quick answers
of whether a treatment intervention is either working
or not can be obtained. Importantly, tumour material
obtained may provide informative clues for future stu-
dies especially if analysed with genomic technologies.
It is difficult to do trials in an orphan disease, mainly
because of the problems of recruiting enough eligible
patients for the trial. In our literature search, we identi-
fied 42 phase I/II trials for sarcoma patients which were
published between 1990 and 2010. However the phase I
trials for general sarcoma (Table 1) are not complete,
this is because or our search criteria. With a PubMed
search you only search the abstract of the article, so if
sarcoma is not mentioned there we didn’tf i n dt h ea r t i -
cle. In phase I trials quite a few different tumour types
are sometimes enrolled and only the one who show
results are mentioned in the abstract. Some of these
articles we found in the Cochrane Controlled Trial Reg-
ister or the ClinicalTrials.gov database, but not all trials
are registered in these databases. Except with a very
wide PubMed search using (phase 1) as only search cri-
teria we don’t think that it is possible to find all phase I
trials enrolling sarcoma patients.
Of the trials we did found with our search criteria
twenty-one were phase I, two phase I/II and nineteen
phase II trials. Only eight clinical trials included only
Ewing sarcoma patients; of this group two were phase I
and six were phase II trials. We found only twenty trials
which included only osteosarcoma patients. There were
two phase I, sixteen phase II, and two phase I/II trials.
A total of 3,736 patients were included in the clinical
trials, of which 1,263 were Ewing sarcoma and 1,114
were osteosarcoma patients. From the identified trials,
the results are not convincing for benefit and most of
the time even disappointing, from osteosarcoma trials
we found 8% CR, 2.8% PR and 4% SD. For Ewing sar-
coma the results are 9.5% CR, 7.5% PR and 3% SD. And
if the drugs seem to be effective, a lot of toxicity is
reported (Tables 1, 2, 3, 4). Looking at the number of
trials we found for sarcoma patients, the results seem
encouraging as a high number of patients were included.
However, if we make a calculation of the number of
new Ewing sarcoma patients expected in the last twenty
years, assuming a world population of five billion and
an incidence of 2 in 1.000,000, approximately 200,000
new cases would be expected in twenty years world-
wide. Of these patients, we could only find 1,263
reported and included in published clinical trials. For
osteosarcoma the number is even worse, with 500,000
new cases expected in twenty years and only 1,114
reported in trials.
To improve these results changes in conducting trials
for orphan state diseases have to be made. It is impor-
tant to collaborate between nations; the Sarcoma Alli-
ance for Research through Collaboration (SARC) is a
good example based principally in North America.
SARC is a non-profit organization started in 2003.
Funding is provided by generous donations, sponsors
and grants. SARC works with healthcare professionals as
part of a collaborative multidisciplinary team from over
35 institutions in the USA. It works with a number of
international institutions and provides the infrastructure
for collaboration between physicians, researchers, and
medical institutions from across the worlds who are
engaged in clinical research for development of new
standards of sarcoma patient treatment, education, and
prevention. This organization facilitates dialogue and
collaboration among sarcoma researchers and clinicians,
assists in the development and dissemination of proto-
cols for clinical trials and information relating to sar-
coma research and the results of clinical trials,
administers research grants and funding for clinical
trials, and acts as a primary resource for those treating
patients with sarcoma. The EORTC Soft Tissue and
Bone Sarcoma Group is one of SARC’s European coun-
terpart, conducting multicenter academic studies in sar-
coma, including some early stage translational studies,
although it’s main contribution in the past has been in
the field of larger phase III trials soft tissue sarcoma.
The European Osteosarcoma Intergroup, EURAMOS
and EuroEwing consortium are examples of groups act-
ing primarily as platforms for phase III studies in bone
sarcomas.
The EC-granted European network, EuroBoNeT
http://www.eurobonet.eu, was the first central organized
n e t w o r ko fe x c e l l e n c ef o ri n t e g r a t e db o n es a r c o m a
research and staff exchange, in order to increase and
disseminate knowledge of primary bone tumours at the
molecular level for development of new tools for patient
care. This integration, exchange of material (virtual Bio-
Bank), standard operating protocols and the use of tech-
nology platforms enabled researchers to obtain
statistically significant datasets, otherwise not achievable
due to the rareness of the condition and the large num-
ber of sub-entities. Without these kinds of collabora-
tions, the development of new treatment strategies in
osteosarcoma and Ewing sarcoma is going to be very
difficult. But perhaps most importantly is that phase I/II
clinical trials have to be conducted. To achieve this
funding needs to be established from industry and gov-
ernments to feed through these collaborative structures
over time frames that might result in enduring progress.
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ing of EuroSarc, European trials in rare sarcomas within
an integrated translational trial network (2011-2016). In
this new translational trial network, the challenges of
combining high quality disease research into clinical
trials in being addressed, and progresses the field
beyond conventional trials and the existing clinical trial
networks.
In addition to the challenge of identifying the most
promising agents for clinical trials in bone sarcoma,
obstacles inherent to this disease further complicate
the successful design and completion of trials of novel
agents. In evaluating the efficacy of novel agents, the
standard approach is to use objective response criteria,
such as Response Evaluation Criteria in Solid Tumours
(RECIST) [19], to compare the size and/or volume of
lesions pre-treatment and at regular intervals during
and post-treatment. New methods for tumour response
which may be more precise are radiological response
based on new criteria, e.g.
18FDG-PET-CT and con-
trast enhanced MRI. For a patient to be eligible for a
trial using this approach, he or she must have measur-
able disease. The traditional approach for patients with
relapsed bone sarcoma, in particular pulmonary
relapse, has been surgical resection, which at least tem-
porarily renders a patient free of radiographic measur-
able disease and thus, ineligible for most trials of novel
agents. Unfortunately novel targeted therapies may be
most effective in the setting of minimal residual dis-
ease. The use of creative surrogate end points to esti-
mate response and perhaps render the combination of
surgical resection and treatment on trials of new
agents not mutually exclusive would allow for better
evaluation of new therapies in patients with bone sar-
coma [20].
When conducting the literature search we found that
the results of many trials are not published. We can
only guess what the reason for this is, but is seems logi-
cal that the trial results were disappointing. From the
phase I/II trials only a very limited number of treat-
ments proceeded to phase III trial. For Ewing sarcoma
we found three clinical trials conducted in the last
twenty years and two trials which are being recruiting at
this moment and for osteosarcoma we found twenty-
two phase III clinical trials and four active trials cur-
rently recruiting patients and one is ongoing trial but
not recruiting.
Most of the phase I/II trials that have been conducted
recruited patients with general sarcoma or solid
tumours. In these trials it is very difficult to say anything
about disease specific response and it is therefore almost
impossible to translate the results to clinical practise
and patients with a specific sort of cancer. Of course it
is understandable why researchers test a drug in
different patient populations in the same trial, especially
is rare cancers like bone sarcoma, but it makes it more
difficult to proceed to a disease specific phase II or even
phase III trial.
While the current standard of care continues to be
multi-agent chemotherapy and surgical resection, it is
clear that further intensification of traditional che-
motherapy regimens is limited by toxicity, and new
approaches are needed. Some promising novel agents
are currently in or are entering into phase II trials in
children with relapsed bone sarcoma. For example, Mur-
amyl Tripeptide Phosphatidylethanolamine (MTP-PE) is
the first drug to be approved for osteosarcoma in Eur-
ope for ten years [21]. In Ewing sarcoma the identifica-
tion of the Insulin-like Growth Factor 1 Receptor
(IGF1R) pathway deregulation, as a consequence of the
EWS-FLI1 translocation seems to be a new treatment
strategy to be explored. The incorporation of these new
treatments into the up-front therapy for bone sarcoma
i nt h en e a rf u t u r eh o l d sp r o m i s ef o ri m p r o v i n g
outcomes.
Lists of abbreviations
EMEA: European Medicines (Evaluation) Agency; EFS:
Event free survival; IGF1R: Insulin-like Growth Factor 1
Receptor; MTP-PE: Muramyl Tripeptide Phosphatidy-
lethanolamine; OS: Overall survival; PET: Positron emis-
sion tomography; PFS: Progression free survival;
RECIST: Response Evaluation Criteria in Solid Tumours;
SARC: Sarcoma Alliance for Research through Colla-
boration network.
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